Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab

European Journal of Haematology

Volumn 87, Issue 6, 2011, Pages 473-479

  Röth, Alexander ^a   Dührsen, Ulrich ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Eculizumab; Paroxysmal nocturnal hemoglobinuria; Terminal complement inhibitor; Therapy

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C5; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; ECULIZUMAB; FOLIC ACID; GLYCOSYLPHOSPHATIDYLINOSITOL; IRON;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTICOAGULATION; BLOOD TRANSFUSION; COMPLEMENT ACTIVATION; DRUG EFFICACY; ERYTHROCYTE; FATIGUE; HEMATOPOIETIC STEM CELL; HUMAN; MORTALITY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT MONITORING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SUPPLEMENTATION; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MONITORING, PHYSIOLOGIC; STEM CELL TRANSPLANTATION; THROMBOSIS;

EID: 81255147127     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01701.x     Document Type: Review

References (55)

1. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699-709.
2. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-8.
3. de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008;112:3099-106.
4. Röth A, Dührsen U. Paroxysmal nocturnal hemoglobinuria. Dtsch Arztebl 2007;104:A192-7.
5. Röth A, Dührsen U, Schrezenmeier H, Schubert J. Paroxysmal nocturnal hemoglobinuria (PNH). Dtsch Med Wochenschr 2009;134:404-9.
6. Gull WW. A case of intermittent haematinuria. Guys Hosp Rep 1866;12:381.
7. Strübing P. Paroxysmale Haemoglobinurie. Dtsch Med Wochenschr 1882;8:1-17.
8. Crosby WH. Paroxysmal nocturnal hemoglobinuria; a classic description by Paul Strübing in 1882, and a bibliography of the disease. Blood 1951;6:270-84.
9. Marchiafava E, Nazari A. Nuovo contributo allo studio degli itteri cronici emolitici. Policlinico Med 1911;18:241-54.
10. Micheli F. Un caso di anemia emolitica con emosiderinuria perpetua. Accad Medica 1928;7:148.
11. Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, Takahashi M, Kitani T, Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-11.
12. Bessler M, Mason PJ, Hillmen P, Miyata T, Yamada N, Takeda J, Luzzatto L, Kinoshita T. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994;13:110-7.
13. Parker CJ. Molecular basis of paroxysmal nocturnal hemoglobinuria. Stem Cells 1996;14:396-411.
14. Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990;323:1184-9.
15. Motoyama N, Okada N, Yamashina M, Okada H. Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur J Immunol 1992;22:2669-73.
16. Bessler M, Fehr J. Fc III receptors (FcRIII) on granulocytes: a specific and sensitive diagnostic test for paroxysmal nocturnal hemoglobinuria (PNH). Eur J Haematol 1991;47:179-84.
17. Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996;87:5332-40.
18. Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT, Borowitz MJ. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000;114:459-66.
19. Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 2000;42:223-33.
20. Richards SJ, Barnett D. The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory. Clin Lab Med 2007;27:577-90, vii.
21. Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, Wittwer CT, Richards SJ. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010;78:211-30.
22. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293:1653-62.
23. Rosse WF, Nishimura J. Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems. Int J Hematol 2003;77:113-20.
24. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996;33:1389-401.
25. Saso R, Marsh J, Cevreska L, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999;104:392-6.
26. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-64.
27. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43.
28. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840-7.
29. Schubert J, Hillmen P, Röth A, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142:263-72.
30. Röth A, Hock C, Konik A, Christoph S, Dührsen U. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int J Hematol 2011;93:704-14.
31. Risitano AM, Marando L, Seneca E, Rotoli B. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood 2008;112:449-51.
32. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009;113:4094-100.
33. Röth A, Peine S, Dührsen U. Paroxysmal nocturnal hemoglobinuria turning Coombs-positive. Int J Hematol 2010;91:159-60.
34. Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010;85:553-9.
35. Liebman HA, Feinstein DI. Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res 2003;111:235-8.
36. Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-8.
37. Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, Duval A, Schved JF, Fischer AM, Socie G. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 2010;95:574-81.
38. Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010;149:414-25.
39. Dacie JV, Lewis SM. Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease. Ser Haematol 1972;5:3-23.
40. Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. Blood 1982;60:20-3.
41. Kuo GP, Brodsky RA, Kim HS. Catheter-directed thrombolysis and thrombectomy for the Budd-Chiari syndrome in paroxysmal nocturnal hemoglobinuria in three patients. J Vasc Interv Radiol 2006;17:383-7.
42. McMullin MF, Hillmen P, Jackson J, Ganly P, Luzzatto L. Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria. J Intern Med 1994;235:85-9.
43. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003;102:3587-91.
44. Emadi A, Brodsky RA. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Am J Hematol 2009;84:699-701.
45. Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010;149:446-50.
46. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009;147:43-70.
47. Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant 2010;16:S119-25.
48. Fieni S, Bonfanti L, Gramellini D, Benassi L, Delsignore R. Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review. Obstet Gynecol Surv 2006;61:593-601.
49. Marasca R, Coluccio V, Santachiara R, Leonardi G, Torelli G, Notaro R, Luzzatto L. Pregnancy in PNH: another eculizumab baby. Br J Haematol 2010;150:707-8.
50. Kelly R, Hill A, Mitchell LD, Richards SJ, Arnold LM, Valters GL, Cullen M, Cohen DR, Gregory WM, Hillmen P. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria (PNH): sustained efficacy and improved survival. Blood 2010;116:639.
51. Brodsky R, de Castro C, Schrezenmeier H, et al. Long term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 2010;116:4237.
52. Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:542-4.
53. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:544-6.
54. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009;9:231-5.
55. Röth A, Hüttmann A, Rother RP, Dührsen U, Philipp T. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 2009;113:3885-6.